Terrence Higgins Trust uses cookies to improve your experience of our websites. For more information or to change the use of cookies, please click here.

Accept and Close

Kivexa (abacavir + lamivudine)


Generic name: abacavir and lamivudine, also called 3TC

Brand names: Kivexa (EU) and Epzicom (US)

Class: Combined NRTI (nukes) tablets


Common (affecting up to 1 in 10 people): Hypersensitivity reaction*, rash, nausea, vomiting, diarrhoea, fever, headache, tiredness, loss of appetite, stomach pain, hair loss, insomnia (difficulty sleeping), general feeling of being unwell, runny nose, cough, joint pain, muscle pain.

Uncommon side effects (affecting up to 1 in 100 people): Anaemia (a low red blood cell count), neutropenia (a low white blood cell count), thrombocytopenia (a decrease in the number of cells involved in blood clotting), an increase in liver enzymes. These side effects would show up in blood tests.


Tablet comprises 600mg abacavir and 300mg lamivudine.

Take one tablet once a day.


Take with or without food.

*If you are planning to take Kivexa, or any treatment containing abacavir, your doctor should carry out a blood test for a gene called HLA-B*5701. You're more likely to have a hypersensitivity reaction to abacavir if you have this gene. If the test shows that you do have the gene, you should not take Kivexa, or any other treatment containing abacavir.

Last reviewed on 19/12/2016 Next review: 19/12/2019

Any questions? Email feedback@tht.org.uk Information included on this website was correct at the time of publication.

Data and image supplied by NAM.

Further information on this drug from NAM